Latest Brain Health News

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.

Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Compumedics has reported record-breaking sales orders and revenues for FY25, driven by strong US market growth and SaaS adoption, setting the stage for an ambitious FY26 expansion.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.